|

Prospective Validation of the OHI Index

RECRUITINGSponsored by Meir Medical Center
Actively Recruiting
SponsorMeir Medical Center
Started2021-03-03
Est. completion2030-03-03
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05882175

Summary

Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with hematologic malignancies
* At least 18 years old

Exclusion Criteria:

* Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)

Conditions6

CancerHLHHematologic MalignancyHematologic NeoplasmsHemophagocytic LymphohistiocytosesHemophagocytic Syndrome

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.